News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2024

Screening and Diagnosing of Ph+ ALL in Adults

The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.

Episodes in this series

EP. 1 Overview of Characteristics Unique to Ph+ ALL

EP. 1 Overview of Characteristics Unique to Ph+ ALL

EP. 2 Timely Detection: Incidence and Prevalence of Ph+ ALL

EP. 2 Timely Detection: Incidence and Prevalence of Ph+ ALL

EP. 3 Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP. 3 Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

Video 4 - "Screening and Diagnosing of Ph+ ALL in Adults"

EP. 4 Screening and Diagnosing of Ph+ ALL in Adults

Video 5 - "Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management"

EP. 5 Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

Video 6 - "Current Front-Line Targeted Treatments in Ph+ ALL"

EP. 6 Current Front-Line Targeted Treatments in Ph+ ALL

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 7 Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 8 PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 9 Value-Based Care Models Optimizing Ph+ ALL Patient Care

VIdeo 10 - "Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL"

EP. 10 Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

Video 11 - "Disparities in Access to Care for Ph+ ALL patients"

EP. 11 Disparities in Access to Care for Ph+ ALL patients

Video 12 - "The Future of Ph+ ALL Treatments"

EP. 12 The Future of Ph+ ALL Treatments

Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"

EP. 13 Concluding Thoughts on Ph+ ALL Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

February 6th 2026

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Debates at the International Stroke Conference 2026 centered on optimal treatment of ischemic stroke in the modern era. | Image credit: Aliaksandr Marko - stock.adobe.com

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026

February 6th 2026

Dr Susan Vadaparampil

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH

ByBrooke McCormick,Susan Vadaparampil, PhD, MPH

February 6th 2026

AJMC letter to the editor

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

ByFranco Nicolae Grados Rodriguez

February 6th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text